J Woo1, S Santasusagna1, J Banks2, S Pastor-Lopez3, K Yadav4, M Carceles-Cordon1, A Dominguez-Andres1, R B Den5,6, L R Languino6, R Pippa1, C D Lallas7, G Lu-Yao1, W K Kelly1, K E Knudsen6, V Rodriguez-Bravo6, A K Tewari4, J M Prats3, B E Leiby2, L G Gomella7, Josep Domingo-Domenech1,6. 1. Medical Oncology Department, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. 2. Division of Biostatistics and Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. 3. Urology Department, Hospital Sant Jaume Calella, Barcelona, Spain. 4. Urology Department, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Radiation Oncology Department, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. 6. Cancer Biology Department, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. 7. Urology Department, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract
PURPOSE: Prostate specific antigen has limited performance in detecting prostate cancer. The transcription factor GATA2 is expressed in aggressive prostate cancer. We analyzed the predictive value of urine extracellular vesicle GATA2 mRNA alone and in combination with a multigene panel to improve detection of prostate cancer and high risk disease. MATERIALS AND METHODS: GATA2 mRNA was analyzed in matched extracellular vesicles isolated from urines before and after prostatectomy (16) and paired urine and tissue prostatectomy samples (19). Extracellular vesicle GATA2 mRNA performance to distinguish prostate cancer and high grade disease was tested in training (52) and validation (165) cohorts. The predictive value of a multigene score including GATA2, PCA3 and TMPRSS2-ERG (GAPT-E) was tested in both cohorts. RESULTS: Confirming its prostate origin, urine extracellular vesicle GATA2 mRNA levels decreased significantly after prostatectomy and correlated with prostate cancer tissue GATA2 mRNA levels. In the training and validation cohort GATA2 discriminated prostate cancer (AUC 0.74 and 0.66) and high grade disease (AUC 0.78 and 0.65), respectively. Notably, the GAPT-E score improved discrimination of prostate cancer (AUC 0.84 and 0.72) and high grade cancer (AUC 0.85 and 0.71) in both cohorts when compared with each biomarker alone and PT-E (PCA3 and TMPRSS2-ERG). A GAPT-E score for high grade prostate cancer would avoid 92.1% of unnecessary prostate biopsies, compared to 61.9% when a PT-E score is used. CONCLUSIONS: Urine extracellular vesicle GATA2 mRNA analysis improves the detection of high risk prostate cancer and may reduce the number of unnecessary biopsies.
PURPOSE:Prostate specific antigen has limited performance in detecting prostate cancer. The transcription factor GATA2 is expressed in aggressive prostate cancer. We analyzed the predictive value of urine extracellular vesicle GATA2 mRNA alone and in combination with a multigene panel to improve detection of prostate cancer and high risk disease. MATERIALS AND METHODS:GATA2 mRNA was analyzed in matched extracellular vesicles isolated from urines before and after prostatectomy (16) and paired urine and tissue prostatectomy samples (19). Extracellular vesicle GATA2 mRNA performance to distinguish prostate cancer and high grade disease was tested in training (52) and validation (165) cohorts. The predictive value of a multigene score including GATA2, PCA3 and TMPRSS2-ERG (GAPT-E) was tested in both cohorts. RESULTS: Confirming its prostate origin, urine extracellular vesicle GATA2 mRNA levels decreased significantly after prostatectomy and correlated with prostate cancer tissue GATA2 mRNA levels. In the training and validation cohort GATA2 discriminated prostate cancer (AUC 0.74 and 0.66) and high grade disease (AUC 0.78 and 0.65), respectively. Notably, the GAPT-E score improved discrimination of prostate cancer (AUC 0.84 and 0.72) and high grade cancer (AUC 0.85 and 0.71) in both cohorts when compared with each biomarker alone and PT-E (PCA3 and TMPRSS2-ERG). A GAPT-E score for high grade prostate cancer would avoid 92.1% of unnecessary prostate biopsies, compared to 61.9% when a PT-E score is used. CONCLUSIONS: Urine extracellular vesicle GATA2 mRNA analysis improves the detection of high risk prostate cancer and may reduce the number of unnecessary biopsies.
Authors: James McKiernan; Michael J Donovan; Eric Margolis; Alan Partin; Ballentine Carter; Gordon Brown; Phillipp Torkler; Mikkel Noerholm; Johan Skog; Neal Shore; Gerry Andriole; Ian Thompson; Peter Carroll Journal: Eur Urol Date: 2018-09-17 Impact factor: 20.096
Authors: Jessica L Robinson; Katherine S Tzou; Alexander S Parker; Michael G Heckman; Kevin J Wu; Tracy W Hilton; Thomas M Pisansky; Steven E Schild; Jennifer L Peterson; Laura A Vallow; Steven J Buskirk Journal: Br J Radiol Date: 2017-06-16 Impact factor: 3.039
Authors: Heidi A van Vugt; Monique J Roobol; Ries Kranse; Liisa Määttänen; Patrik Finne; Jonas Hugosson; Chris H Bangma; Fritz H Schröder; Ewout W Steyerberg Journal: Eur J Cancer Date: 2010-12-14 Impact factor: 9.162
Authors: Scott A Tomlins; John R Day; Robert J Lonigro; Daniel H Hovelson; Javed Siddiqui; L Priya Kunju; Rodney L Dunn; Sarah Meyer; Petrea Hodge; Jack Groskopf; John T Wei; Arul M Chinnaiyan Journal: Eur Urol Date: 2015-05-16 Impact factor: 20.096
Authors: M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs Journal: Cancer Res Date: 1999-12-01 Impact factor: 12.701
Authors: Bin He; Rainer B Lanz; Warren Fiskus; Chuandong Geng; Ping Yi; Sean M Hartig; Kimal Rajapakshe; John Shou; Liping Wei; Shrijal S Shah; Christopher Foley; Sue Anne Chew; Vijay K Eedunuri; Diego J Bedoya; Qin Feng; Takashi Minami; Constantine S Mitsiades; Anna Frolov; Nancy L Weigel; Susan G Hilsenbeck; Daniel G Rosen; Timothy Palzkill; Michael M Ittmann; Yongcheng Song; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades Journal: Proc Natl Acad Sci U S A Date: 2014-12-08 Impact factor: 11.205
Authors: Veronica Rodriguez-Bravo; Raffaella Pippa; Won-Min Song; Marc Carceles-Cordon; Ana Dominguez-Andres; Naoto Fujiwara; Jungreem Woo; Anna P Koh; Adam Ertel; Ravi K Lokareddy; Alvaro Cuesta-Dominguez; Rosa S Kim; Irene Rodriguez-Fernandez; Peiyao Li; Ronald Gordon; Hadassa Hirschfield; Josep M Prats; E Premkumar Reddy; Alessandro Fatatis; Daniel P Petrylak; Leonard Gomella; W Kevin Kelly; Scott W Lowe; Karen E Knudsen; Matthew D Galsky; Gino Cingolani; Amaia Lujambio; Yujin Hoshida; Josep Domingo-Domenech Journal: Cell Date: 2018-08-09 Impact factor: 66.850
Authors: Manuel Ramirez-Garrastacho; Cristina Bajo-Santos; Jesus Martinez de la Fuente; Maria Moros; Carolina Soekmadji; Kristin Austlid Tasken; Aija Line; Elena S Martens-Uzunova; Alicia Llorente Journal: Br J Cancer Date: 2021-11-22 Impact factor: 7.640